Patrick Weydt

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8303507/publications.pdf

Version: 2024-02-01

101 papers	5,668 citations	94433 37 h-index	79698 73 g-index
106 all docs	106 docs citations	106 times ranked	8182 citing authors

#	Article	IF	Citations
1	Use and subjective experience of the impact of motor-assisted movement exercisers in people with amyotrophic lateral sclerosis: a multicenter observational study. Scientific Reports, 2022, 12, .	3.3	2
2	A Remote Digital Monitoring Platform to Assess Cognitive and Motor Symptoms in Huntington Disease: Cross-sectional Validation Study. Journal of Medical Internet Research, 2022, 24, e32997.	4.3	15
3	Chitotriosidase as biomarker for early stage amyotrophic lateral sclerosis: a multicenter study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 276-286.	1.7	14
4	Effect of Body Weight on Age at Onset in Huntington Disease. Neurology: Genetics, 2021, 7, e603.	1.9	7
5	Teaching an old dog new tricks: serum troponin T as a biomarker in amyotrophic lateral sclerosis. Brain Communications, 2021, 3, fcab274.	3.3	10
6	Proteomics in cerebrospinal fluid and spinal cord suggests UCHL1, MAP2 and GPNMB as biomarkers and underpins importance of transcriptional pathways in amyotrophic lateral sclerosis. Acta Neuropathologica, 2020, 139, 119-134.	7.7	73
7	Deficits in verbal fluency in presymptomatic C9orf72 mutation gene carriersâ€"a developmental disorder. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1195-1200.	1.9	42
8	Different CSF protein profiles in amyotrophic lateral sclerosis and frontotemporal dementia with C9orf72 hexanucleotide repeat expansion. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 503-511.	1.9	33
9	The psychopharmacology of Huntington disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2019, 165, 179-189.	1.8	8
10	Reply: Adult-onset distal spinal muscular atrophy: a new phenotype associated with KIF5A mutations. Brain, 2019, 142, e67-e67.	7.6	1
11	Genotypes of amyotrophic lateral sclerosis in Mongolia. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1300-1302.	1.9	1
12	Routine Cerebrospinal Fluid (CSF) Parameters in Patients With Spinal Muscular Atrophy (SMA) Treated With Nusinersen. Frontiers in Neurology, 2019, 10, 1179.	2.4	18
13	Different neuroinflammatory profile in amyotrophic lateral sclerosis and frontotemporal dementia is linked to the clinical phase. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 4-10.	1.9	96
14	The metabolic and endocrine characteristics in spinal and bulbar muscular atrophy. Journal of Neurology, 2018, 265, 1026-1036.	3.6	29
15	Hot-spot KIF5A mutations cause familial ALS. Brain, 2018, 141, 688-697.	7.6	167
16	Comprehensive analysis of the mutation spectrum in 301 German ALS families. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 817-827.	1.9	80
17	Provision of assistive technology devices among people with ALS in Germany: a platform-case management approach. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 342-350.	1.7	33
18	Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. Neurology, 2018, 90, e22-e30.	1.1	148

#	Article	IF	Citations
19	Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 239-247.	1.9	89
20	H33â€...The swallowing disorder in huntingtonâ€™s disease (hd): an observational study â€“ nutritional aspects. , 2018, , .		0
21	Thermoregulatory disorders in Huntington disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 157, 761-775.	1.8	6
22	Thermoregulation in amyotrophic lateral sclerosis. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 157, 749-760.	1.8	7
23	Serum irisin is upregulated in patients affected by amyotrophic lateral sclerosis and correlates with functional and metabolic status. Journal of Neurology, 2018, 265, 3001-3008.	3.6	20
24	Safety, tolerability, and preliminary efficacy of an IGF-1 mimetic in patients with spinal and bulbar muscular atrophy: a randomised, placebo-controlled trial. Lancet Neurology, The, 2018, 17, 1043-1052.	10.2	28
25	A novel CHCHD10 mutation implicates a Mia40â€dependent mitochondrial import deficit in ALS. EMBO Molecular Medicine, 2018, 10, .	6.9	43
26	Telomere length as a modifier of age-at-onset in Huntington disease: a two-sample Mendelian randomization study. Journal of Neurology, 2018, 265, 2149-2151.	3.6	8
27	H31â€...Dysphagia in huntingtonÂ´s disease â€“ an observational study. , 2018, , .		1
28	H32â€...Neuronal correlates and clinical predictors for dysphagia in huntingtonâ€™s disease. , 2018, , .		0
29	Polyâ€‹<scp>GP</scp> in cerebrospinal fluid links C9orf72â€associated dipeptide repeat expression to the asymptomatic phase of <scp>ALS</scp>/<scp>FTD</scp>. EMBO Molecular Medicine, 2017, 9, 859-868.	6.9	90
30	Hypothalamic atrophy is related to body mass index and age at onset in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 1033-1041.	1.9	113
31	Evaluation of monoacylglycerol lipase as a therapeutic target in a transgenic mouse model of ALS. Neuropharmacology, 2017, 124, 157-169.	4.1	32
32	Novel Blood-Based Biomarkers of Cognition, Stress, and Physical or Cognitive Training in Older Adults at Risk of Dementia: Preliminary Evidence for a Role of BDNF, Irisin, and the Kynurenine Pathway. Journal of Alzheimer's Disease, 2017, 59, 1097-1111.	2.6	68
33	July 2017 ENCALS statement on edaravone. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 471-474.	1.7	41
34	Ribosomal transcription is regulated by PGC-1alpha and disturbed in Huntingtonâ€™s disease. Scientific Reports, 2017, 7, 8513.	3.3	31
35	Contrasting effects of selective MAGL and FAAH inhibition on dopamine depletion and GDNF expression in a chronic MPTP mouse model of Parkinson's disease. Neurochemistry International, 2017, 110, 14-24.	3.8	34
36	The concept and diagnostic criteria of primary lateral sclerosis. Acta Neurologica Scandinavica, 2017, 136, 204-211.	2.1	32

#	Article	IF	Citations
37	ALS-causing mutations differentially affect PGC-1Î± expression and function in the brain vs. peripheral tissues. Neurobiology of Disease, 2017, 97, 36-45.	4.4	35
38	Targeting Neuroinflammation to Treat Alzheimerâ€™s Disease. CNS Drugs, 2017, 31, 1057-1082.	5.9	182
39	Comparison of Sirtuin 3 Levels in ALS and Huntingtonâ€™s Diseaseâ€"Differential Effects in Human Tissue Samples vs. Transgenic Mouse Models. Frontiers in Molecular Neuroscience, 2017, 10, 156.	2.9	30
40	High-resolution respirometry of fine-needle muscle biopsies in pre-manifest Huntingtonâ€™s disease expansion mutation carriers shows normal mitochondrial respiratory function. PLoS ONE, 2017, 12, e0175248.	2.5	11
41	Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, jnnp-2015-311387.	1.9	207
42	B30â€…Integrated mitochondrial function in human fine-needle muscle biopsies of huntingtonâ€™s disease mutation carriers and in tissues of HdhQ111 mice. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A19.3-A20.	1.9	0
43	Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis. Annals of Neurology, 2016, 79, 152-158.	5.3	188
44	H2â€…Dysphagia in huntingtonâ€™s disease (HD): a longitudinal, observational study. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A57.1-A57.	1.9	17
45	B21â€…Ribosomal transcription is regulated by PGC-1alpha and disturbed in huntingtonâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A16.2-A16.	1.9	0
46	Towards a European Registry and Biorepository for Patients with Spinal and Bulbar Muscular Atrophy. Journal of Molecular Neuroscience, 2016, 58, 394-400.	2.3	10
47	Clinical Trials in Spinal and Bulbar Muscular Atrophyâ€"Past, Present, and Future. Journal of Molecular Neuroscience, 2016, 58, 379-387.	2.3	15
48	Peripheral monocytes are functionally altered and invade the CNS in ALS patients. Acta Neuropathologica, 2016, 132, 391-411.	7.7	116
49	NEK1mutations in familial amyotrophic lateral sclerosis. Brain, 2016, 139, e28-e28.	7.6	105
50	Screening forCHCHD10mutations in a large cohort of sporadic ALS patients: no evidence for pathogenicity of the p.P34S variant: Table 1. Brain, 2016, 139, e8-e8.	7.6	20
51	Comparative biochemical characterization of the monoacylglycerol lipase inhibitor KML29 in brain, spinal cord, liver, spleen, fat and muscle tissue. Neuropharmacology, 2015, 91, 148-156.	4.1	32
52	Serum microRNAs in sporadic amyotrophic lateral sclerosis. Neurobiology of Aging, 2015, 36, 2660.e15-2660.e20.	3.1	64
53	Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nature Neuroscience, 2015, 18, 631-636.	14.8	652
54	Mutual exacerbation of peroxisome proliferatorâ€activated receptor Î³ coactivator 1Î± deregulation and Î±â€synuclein oligomerization. Annals of Neurology, 2015, 77, 15-32.	5.3	112

#	Article	IF	Citations
55	Two-Point Magnitude MRI for Rapid Mapping of Brown Adipose Tissue and Its Application to the R6/2 Mouse Model of Huntington Disease. PLoS ONE, 2014, 9, e105556.	2.5	15
56	Development, Implementation, and Evaluation of a Movie-Based Curriculum to Teach Psychopathology. Teaching and Learning in Medicine, 2014, 26, 86-89.	2.1	13
57	A single nucleotide polymorphism in the coding region of PGC-1Î± is a male-specific modifier of Huntington disease age-at-onset in a large European cohort. BMC Neurology, 2014, 14, 1.	1.8	137
58	Can lesions to the motor cortex induce amyotrophic lateral sclerosis?. Journal of Neurology, 2014, 261, 283-290.	3.6	20
59	Monocyte subtypes in ALS. Journal of Neuroimmunology, 2014, 275, 94.	2.3	0
60	Serum microRNAs in patients with genetic amyotrophic lateral sclerosis and pre-manifest mutation carriers. Brain, 2014, 137, 2938-2950.	7.6	91
61	Incidence and Geographical Variation of Amyotrophic Lateral Sclerosis (ALS) in Southern Germany â€“ Completeness of the ALS Registry Swabia. PLoS ONE, 2014, 9, e93932.	2.5	47
62	Prodromal Huntington Disease as a Model for Functional Compensation of Early Neurodegeneration. PLoS ONE, 2014, 9, e114569.	2.5	32
63	Full-length PGC-1Î± salvages the phenotype of a mouse model of human neuropathy through mitochondrial proliferation. Human Molecular Genetics, 2013, 22, 5096-5106.	2.9	3
64	Genetische Diagnostik der amyotrophen Lateralsklerose. Medizinische Genetik, 2013, 25, 352-357.	0.2	1
65	Dynein mutations associated with hereditary motor neuropathies impair mitochondrial morphology and function with age. Neurobiology of Disease, 2013, 58, 220-230.	4.4	40
66	PGC-1Â is a male-specific disease modifier of human and experimental amyotrophic lateral sclerosis. Human Molecular Genetics, 2013, 22, 3477-3484.	2.9	74
67	Neuropathology of Partial PGC-1Î± Deficiency Recapitulates Features of Mitochondrial Encephalopathies but Not of Neurodegenerative Diseases. Neurodegenerative Diseases, 2013, 12, 177-188.	1.4	17
68	A greatly extended PPARGC1A genomic locus encodes several new brain-specific isoforms and influences Huntington disease age of onsetâ€. Human Molecular Genetics, 2012, 21, 3461-3473.	2.9	85
69	Progranulin Bridges Energy Homeostasis and Fronto-Temporal Dementia. Cell Metabolism, 2012, 15, 269-270.	16.2	4
70	Hypogonadism and Gynecomastia with Duloxetine. Pharmacopsychiatry, 2011, 44, 77-77.	3.3	6
71	Etiology, Pathology, and Pathogenesis. Blue Books of Neurology, 2010, , 417-431.	0.1	0
72	The Role of PGC-1α in the Pathogenesis of Neurodegenerative Disorders. Current Drug Targets, 2010, 11, 1262-1269.	2.1	65

#	Article	IF	Citations
73	The gene coding for PGC-1Î± modifies age at onset in Huntington's Disease. Molecular Neurodegeneration, 2009, 4, 3.	10.8	119
74	Myositis associated with localized lipodystrophy: an unrecognized condition?. European Journal of Medical Research, 2009, 14, 228-30.	2.2	2
75	Targeting protein aggregation in neurodegeneration â€“ lessons from polyglutamine disorders. Expert Opinion on Therapeutic Targets, 2006, 10, 505-513.	3.4	21
76	Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1Î± in Huntington's disease neurodegeneration. Cell Metabolism, 2006, 4, 349-362.	16.2	519
77	Neuroinflammation in the pathogenesis of amyotrophic lateral sclerosis. NeuroReport, 2005, 16, 527-531.	1.2	79
78	Targeting toxic proteins for turnover. Nature Medicine, 2005, 11, 1052-1053.	30.7	5
79	Modafinil to treat fatigue in amyotrophic lateral sclerosis: An open label pilot study. American Journal of Hospice and Palliative Medicine, 2005, 22, 55-59.	1.4	65
80	The Role of Microglial Cells in Amyotrophic Lateral Sclerosis. Physical Medicine and Rehabilitation Clinics of North America, 2005, 16, 1081-1090.	1.3	8
81	Skeletal Muscle in Amyotrophic Lateral Sclerosis: Emerging Concepts and Therapeutic Implications. Physical Medicine and Rehabilitation Clinics of North America, 2005, 16, 1091-1097.	1.3	5
82	Cannabinol delays symptom onset in SOD1 (G93A) transgenic mice without affecting survival. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2005, 6, 182-184.	2.1	86
83	Endocannabinoids accumulate in spinal cord of SOD1 G93A transgenic mice. Journal of Neurochemistry, 2004, 89, 1555-1557.	3.9	93
84	Increased cytotoxic potential of microglia from ALSâ€transgenic mice. Glia, 2004, 48, 179-182.	4.9	135
85	Current pharmacological management of amyotropic lateral sclerosis and a role for rational polypharmacy. Expert Opinion on Pharmacotherapy, 2004, 5, 735-746.	1.8	22
86	Survey of cannabis use in patients with amyotrophic lateral sclerosis. American Journal of Hospice and Palliative Medicine, 2004, 21, 95-104.	1.4	77
87	Inflammatory mediators and growth factors in the spinal cord of G93A SOD1 rats. NeuroReport, 2004, 15, 2513-2516.	1.2	36
88	Electrodiagnostic evaluation of hereditary motor and sensory neuropathies. Physical Medicine and Rehabilitation Clinics of North America, 2003, 14, 347-363.	1.3	3
89	Assessing disease onset and progression in the SOD1 mouse model of ALS. NeuroReport, 2003, 14, 1051-1054.	1.2	105
90	Assessing disease onset and progression in the SOD1 mouse model of ALS. NeuroReport, 2003, 14, 1051-1054.	1.2	183

#	Article	IF	Citations
91	Drug therapy for amyotrophic lateral sclerosis: Where are we now?. IDrugs: the Investigational Drugs Journal, 2003, 6, 147-53.	0.7	4
92	Cannabis: old medicine with new promise for neurological disorders. Current Opinion in Investigational Drugs, 2002, 3, 437-40.	2.3	11
93	Austrian body pleads for normal contacts despite EU freeze. Nature, 2000, 403, 691-691.	27.8	2
94	Biomedical centre memorial to victims of Nazi research. Nature, 2000, 403, 816-816.	27.8	1
95	German research agency stifles creativity. Nature, 2000, 404, 217-217.	27.8	1
96	Frustration grows over EU grant application procedures. Nature, 2000, 404, 695-695.	27.8	1
97	Activation of metabotropic glutamate receptors delays apoptosis of chick embryonic motor neurons in vitro. NeuroReport, 1998, 9, 2039-2043.	1.2	35
98	Action Potential-generating Cells in Human Glioblastomas. Journal of Neuropathology and Experimental Neurology, 1997, 56, 243-254.	1.7	59
99	Neuroligand-triggered calcium signalling in cultured human glioma cells. Neuroscience Letters, 1997, 228, 91-94.	2.1	12
100	Neuron-like physiological properties of cells from human oligodendroglial tumors. Neuroscience, 1996, 71, 601-611.	2.3	83
101	Human central neurocytoma cells show neuronal physiological properties in vitro. Acta Neuropathologica, 1996, 91, 209-214.	7.7	22